Long-term surveillance study of rituximab originator treated patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)
Lay Summary: What does this mean for patients? Rituximab is used to treat active disease and to prevent relapses in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Serious complications, including infections, low natural antibody levels, cancers, low white blood cell levels, heart...
Những tác giả chính: | , , , , , , , , , , |
---|---|
Định dạng: | Journal article |
Ngôn ngữ: | English |
Được phát hành: |
Oxford University Press
2024
|